Why the study?
What is the current pharmacological treatment for dealing with perioperative pulmonary hypertensive crisis in PAH-CHD patients?
What is the current pharmacological treatment for dealing with perioperative pulmonary hypertensive crisis in PAH-CHD patients?
Proper perioperative planning and pharmacological management targeting specific signaling pathways can help anticipate complications and optimize surgical outcomes in PAH-CHD patients.
May guide perioperative PAH-CHD management; leaves open need for prospective trials to confirm optimal regimens.
Pulmonary hypertensive crisis is an important cause of morbidity and mortality in patients with pulmonary arterial hypertension secondary to congenital heart disease (PAH-CHD) who require cardiac surgery. At present, prevention and management of perioperative pulmonary hypertensive crisis is aimed at optimizing cardiopulmonary interactions by targeting prostacyclin, endothelin, and nitric oxide signaling pathways within the pulmonary circulation with various pharmacological agents. This review is aimed at familiarizing the practitioner with the current pharmacological treatment for dealing with perioperative pulmonary hypertensive crisis in PAH-CHD patients. Given the life-threatening complications associated with pulmonary hypertensive crisis, proper perioperative planning can help anticipate cardiopulmonary complications and optimize surgical outcomes in this patient population.
No takes yet. Share an insight, caveat, or question.
Brunner et al. (2014) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: